Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and agree to the study's consent process by signing a consent form
• People who are aged 65 years or older at the time of signing the consent form
• People who are able to follow the study visit schedule and meet all study requirements
• People who have been diagnosed with multiple myeloma that has not yet been treated, cannot have a stem cell transplant, and is causing symptoms — confirmed by specific bone marrow or biopsy findings, plus signs of organ damage or certain abnormal blood/imaging results (confirm with trial site for exact diagnostic details)
• People whose general physical functioning is rated at a level of 0, 1, or 2 on a standard medical scale (meaning they are fully active to somewhat limited but able to care for themselves)
• Women who could become pregnant must have a negative pregnancy test and follow the trial's pregnancy prevention guidelines, including using effective contraception or abstaining from heterosexual intercourse
• Men must agree to use a condom or abstain from sexual contact with a pregnant woman or a woman who could become pregnant throughout the study, during any breaks in treatment, and for at least 28 days after stopping the study drug — including men who have had a vasectomy
• People with a life expectancy of at least 3 months
• People who are able to swallow and take oral (by mouth) medications
• People whose recent blood test results (taken within 10 days before starting the study drug) meet specific minimum levels for white blood cells, liver enzymes, kidney function, platelets, and haemoglobin (confirm with trial site for exact values)

Who may not be able to join:

• People who have previously received treatment for multiple myeloma (note: radiotherapy, bone-strengthening medications, or a single short course of steroids may be exceptions — confirm with trial site)
• People with a serious medical condition that would make participation unsafe, such as a recent heart attack (within the past 6 months), severe heart failure, uncontrolled irregular heartbeat or high blood pressure, or conditions requiring ongoing steroid or immune-suppressing treatment (such as rheumatoid arthritis, multiple sclerosis, or lupus)
• People who are pregnant or breastfeeding
• People whose kidneys have failed to the point of requiring dialysis
• People who have had another type of cancer within the past 3 years (some early-stage or non-invasive skin and cervical cancers, as well as certain low-risk prostate findings, may be exceptions — confirm with trial site)
• People who are unable or unwilling to take blood-thinning (antithrombotic) medication
• People with moderate or severe nerve damage affecting the arms or legs (peripheral neuropathy rated at grade 2 or higher)
• People known to be HIV positive, or who have active hepatitis A, B, or C infection
• People diagnosed with a specific type of protein deposit disease called AL amyloidosis, or myeloma complicated by amyloidosis
• People diagnosed with plasma cell leukaemia
• People with certain heart or cardiovascular concerns, including an abnormal heart rhythm measurement on an ECG (QTc interval of 470 milliseconds or more), significant heart rhythm problems, a heart attack or coronary procedure within the past 6 months, severe heart failure (Class III or IV), or uncontrolled high blood pressure
• People with a known allergy or sensitivity to boron, the study drug iberdomide, or any of their ingredients
• People currently taking certain medications that strongly affect how the body processes drugs (strong CYP3A4/5 inhibitors or inducers — confirm with trial site for specific medications)
• People with any serious uncontrolled medical or psychiatric condition that could interfere with the study or pose a safety risk, as determined by the study doctor
• People who have had a COVID-19 infection within 14 days (for mild or no symptoms) or 28 days (for severe illness) before starting the study treatment
• People who have had major surgery within 28 days before starting the study treatment
• People with an active infection that could interfere with the study
• People with a digestive or gastrointestinal condition that could significantly affect how the study drug is absorbed by the body
• People who have received a live vaccine within 3 months before starting the study treatment

Important: Always verify eligibility with the trial site directly before applying.